应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01477 欧康维视生物-B
休市中 11-20 16:08:29
4.555
-0.065
-1.41%
最高
4.745
最低
4.300
成交量
22.25万
今开
4.745
昨收
4.620
日振幅
9.63%
总市值
37.12亿
流通市值
37.12亿
总股本
8.15亿
成交额
99.62万
换手率
0.03%
流通股本
8.15亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
ST天圣最新公告:撤销其他风险警示11月24日起证券简称变更为“天圣制药”
证券之星 · 11-20 20:00
ST天圣最新公告:撤销其他风险警示11月24日起证券简称变更为“天圣制药”
东富龙绿色包装新标准——八项原则下的制药包装整体解决方案
同花顺 · 11-20 18:06
东富龙绿色包装新标准——八项原则下的制药包装整体解决方案
谷歌AI制药完成50亿美金融资:大厂AI制药军备竞赛
蓝鲸财经 · 11-20 18:03
谷歌AI制药完成50亿美金融资:大厂AI制药军备竞赛
港股异动 | 歌礼制药-B(01672.HK)涨近2% 近日向FDA递交ASC36_37o FDC治疗肥胖症的IND
智通财经 · 11-20 11:00
港股异动 | 歌礼制药-B(01672.HK)涨近2% 近日向FDA递交ASC36_37o FDC治疗肥胖症的IND
Arcera生命科学与Innogen制药公司签署独家许可协议,扩大药物获取途径。
格隆汇 · 11-19 17:59
Arcera生命科学与Innogen制药公司签署独家许可协议,扩大药物获取途径。
京东健康(06618)与齐鲁制药达成战略合作,肺癌用药Ⅰ类创新药卡达沙®全网独家首发
智通财经 · 11-19 16:10
京东健康(06618)与齐鲁制药达成战略合作,肺癌用药Ⅰ类创新药卡达沙®全网独家首发
罗氏制药两大项目落地张江,研发生产同步加码,抢占全球医药创新首发权
上观新闻 · 11-18 21:30
罗氏制药两大项目落地张江,研发生产同步加码,抢占全球医药创新首发权
迦南科技:公司主要业务为制药装备
证券之星 · 11-18 20:52
迦南科技:公司主要业务为制药装备
泽璟制药:ZG006关键性临床试验达预设主要终点
证券之星 · 11-18 17:51
泽璟制药:ZG006关键性临床试验达预设主要终点
DeepMind拆分的AI制药企业Isomorphic Labs融资50亿美元 红杉领投
雷递网 · 11-18 14:50
DeepMind拆分的AI制药企业Isomorphic Labs融资50亿美元 红杉领投
大行评级丨招银国际:上调中生制药目标价至9港元,创新药商业化与国际化继续取得突破
格隆汇 · 11-18 13:58
大行评级丨招银国际:上调中生制药目标价至9港元,创新药商业化与国际化继续取得突破
泽璟制药(688266)11月17日主力资金净卖出10.17万元
证券之星 · 11-18
泽璟制药(688266)11月17日主力资金净卖出10.17万元
股市必读:汇宇制药新发布《2026年第二次临时股东会会议资料》
证券之星 · 11-18
股市必读:汇宇制药新发布《2026年第二次临时股东会会议资料》
歌礼制药-B(01672)向美国FDA递交ASC36_37o FDC治疗肥胖症的新药临床试验申请
智通财经 · 11-17
歌礼制药-B(01672)向美国FDA递交ASC36_37o FDC治疗肥胖症的新药临床试验申请
港股异动 | 歌礼制药-B(01672)涨超5% ASC30_48 FDC等临床前研究亮相ObesityWeek
智通财经 · 11-17
港股异动 | 歌礼制药-B(01672)涨超5% ASC30_48 FDC等临床前研究亮相ObesityWeek
股市必读:汇宇制药新发布《2026年第二次临时股东会会议资料》
证券之星 · 11-17
股市必读:汇宇制药新发布《2026年第二次临时股东会会议资料》
歌礼制药-B(01672.HK):歌礼口服与长效注射减重临床前研究亮相ObesityWeek® 2026
智通财经 · 11-16
歌礼制药-B(01672.HK):歌礼口服与长效注射减重临床前研究亮相ObesityWeek® 2026
东吴证券:AI制药从概念验证到商业化落地 中长期关注AI平台型公司
智通财经 · 11-16
东吴证券:AI制药从概念验证到商业化落地 中长期关注AI平台型公司
股市必读:汇宇制药新发布《关于召开2026年第三季度业绩说明会的公告》
证券之星 · 11-16
股市必读:汇宇制药新发布《关于召开2026年第三季度业绩说明会的公告》
汇宇制药(688553)披露2026年第三季度业绩说明会安排,11月13日股价下跌4.29%
证券之星 · 11-13
汇宇制药(688553)披露2026年第三季度业绩说明会安排,11月13日股价下跌4.29%
加载更多
公司概况
公司名称:
欧康维视生物-B
所属市场:
SEHK
上市日期:
--
主营业务:
欧康维视生物是一家主要从事眼科药物的研发和商业化的公司。该公司产品主要包括OT-401“优施莹”氟轻松玻璃体内植入剂、OT-702“博优景”阿柏西普眼内注射溶液、OT-402“维速达尔”注射用维替泊芬、OT-204“欧沁”玻璃酸钠滴眼液及OT-305“贝特舒”盐酸倍他洛尔滴眼液等。该公司产品主要用于治疗葡萄膜炎、眼底疾病、屈光矫正、干眼症(DED)、青光眼及角结膜炎等各种眼前及眼后段疾病。该公司主要在中国国内市场开展业务。
发行价格:
--
{"stockData":{"symbol":"01477","market":"HK","secType":"STK","nameCN":"欧康维视生物-B","latestPrice":4.555,"timestamp":1795162109004,"preClose":4.62,"halted":0,"volume":222500,"delay":0,"changeRate":-0.014069264069264153,"floatShares":815000000,"shares":815000000,"eps":-0.2,"marketStatus":"休市中","change":-0.065,"latestTime":"11-20 16:08:29","open":4.745,"high":4.745,"low":4.3,"amount":996200,"amplitude":0.09632,"askPrice":4.555,"askSize":4000,"bidPrice":4.46,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.1824,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1795397400000},"marketStatusCode":7,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":4.62,"openAndCloseTimeList":[[1795138200000,1795147200000],[1795150800000,1795161600000]],"volumeRatio":0.6267782189458575,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01477","defaultTab":"news","newsList":[{"id":"2684545871","title":"ST天圣最新公告:撤销其他风险警示11月24日起证券简称变更为“天圣制药”","url":"https://stock-news.laohu8.com/highlight/detail?id=2684545871","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684545871?lang=zh_cn&edition=full","pubTime":"2026-11-20 20:00","pubTimestamp":1795176039,"startTime":"0","endTime":"0","summary":"ST天圣(002872.SZ)公告称,公司撤销其他风险警示的申请已获深交所审核同意。公司股票将于11月23日停牌一天,11月24日复牌并撤销其他风险警示,证券简称由“ST天圣”变更为“天圣制药”,股票代码不变,日涨跌幅限制仍为10%。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026112000037093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK1574","BK0250","002872","01477","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684215370","title":"东富龙绿色包装新标准——八项原则下的制药包装整体解决方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2684215370","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684215370?lang=zh_cn&edition=full","pubTime":"2026-11-20 18:06","pubTimestamp":1795169160,"startTime":"0","endTime":"0","summary":"随着医药行业对环保包材与柔性包装能力的要求不断提升,纸托包装方案受到越来越多药企关注。作为国内较早布局纸托包装设备自主研发的企业,东富龙预折式纸托装盒机经过长期研发沉淀与产业化 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261120/c682059286.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261120/c682059286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0251","01477","300171","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684153975","title":"谷歌AI制药完成50亿美金融资:大厂AI制药军备竞赛","url":"https://stock-news.laohu8.com/highlight/detail?id=2684153975","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684153975?lang=zh_cn&edition=full","pubTime":"2026-11-20 18:03","pubTimestamp":1795169031,"startTime":"0","endTime":"0","summary":"文|投资界融资纪录再度被打破——11月17日,Isomorphic Labs宣布完成50亿美元C轮融资,由Greenoaks和Sequoia Capital共同领投,a16z等机构参与,Alphabet继续追加投资。在中国,与Isomorphic几乎同期起步、从字节跳动分拆的Anew Labs也在不久前率先完成20亿人民币融资。其报道标题将Anew称为来自中国的AI生物医药竞争者,并将年度“Endpoints 11”奖项授予Anew。同一年,刘凯在字节跳动内部创立了AI制药部门,成为Anew Labs的前身。Isomorphic的50亿美元融资,显示出资本对AI制药发展空间的强烈期待。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1794996182235205365","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1191","CHAT","ARTY","01477","AGIX","AIPO","BK1574","VTHR","QTOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684718266","title":"港股异动 | 歌礼制药-B(01672.HK)涨近2% 近日向FDA递交ASC36_37o FDC治疗肥胖症的IND","url":"https://stock-news.laohu8.com/highlight/detail?id=2684718266","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684718266?lang=zh_cn&edition=full","pubTime":"2026-11-20 11:00","pubTimestamp":1795143622,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01672","01477","BK1515","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684750922","title":"Arcera生命科学与Innogen制药公司签署独家许可协议,扩大药物获取途径。","url":"https://stock-news.laohu8.com/highlight/detail?id=2684750922","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684750922?lang=zh_cn&edition=full","pubTime":"2026-11-19 17:59","pubTimestamp":1795082364,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["01477","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684926200","title":"京东健康(06618)与齐鲁制药达成战略合作,肺癌用药Ⅰ类创新药卡达沙®全网独家首发","url":"https://stock-news.laohu8.com/highlight/detail?id=2684926200","media":"智通财经","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684926200?lang=zh_cn&edition=full","pubTime":"2026-11-19 16:10","pubTimestamp":1795075842,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,11月18日,京东健康与齐鲁制药正式签署战略合作协议。在此次战略签约的背景下,齐鲁制药从战略合作伙伴同源康医药引进的商业化合作产品Ⅰ类创新药卡达沙当日同步在京东健康全网独家首发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1525562.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0051755006.USD","06618","06978","BK1615","LU0456827905.SGD","MEDX","159992","BK1589","LNGR","SGXZ62798434.SGD","BK1571","BK1574","BK1247","BK1583","BK1591","BK1142","86618","01477","BK1191","BK1515","SGXZ86797644.SGD","BK1161","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684991885","title":"罗氏制药两大项目落地张江,研发生产同步加码,抢占全球医药创新首发权","url":"https://stock-news.laohu8.com/highlight/detail?id=2684991885","media":"上观新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684991885?lang=zh_cn&edition=full","pubTime":"2026-11-18 21:30","pubTimestamp":1795008609,"startTime":"0","endTime":"0","summary":"仅1年时间,一座投资20.4亿元的生物制药基地在张江科学城拔地而起。11月18日,罗氏制药上海生物制药生产基地宣告基建竣工,同时宣布中国药品早期开发卓越中心落地上海。依托本土创新研发与本地生产同步加码,罗氏把大分子生物药本地化生产、全球首次人体试验和端到端新药开发能力布局上海,推动上海跻身其全球研发与制造核心版图,抢占全球医药创新首发权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611183934258340.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611183934258340.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1515","BK1574","01477","159938","BK1191","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684996921","title":"迦南科技:公司主要业务为制药装备","url":"https://stock-news.laohu8.com/highlight/detail?id=2684996921","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684996921?lang=zh_cn&edition=full","pubTime":"2026-11-18 20:52","pubTimestamp":1795006343,"startTime":"0","endTime":"0","summary":"证券之星消息,迦南科技(300412)11月18日在投资者关系平台上答复投资者关心的问题。投资者提问:在Ai制药领域里面最重要的是Ai制药试验室设备,而你们是对口的,请问目前你们企业在这方面有无产品规划?迦南科技回复:您好,公司主要业务为制药装备,持续围绕生命大健康产业做战略布局。公司紧跟行业发展需求,始终保持对人工智能领域等前沿技术的关注,希望可以借助新技术,发掘新场景,不断优化产品体系,提升产品竞争力。感谢关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111800041243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300412","BK0028","BK1191","BK0132","01477","BK1574","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684964499","title":"泽璟制药:ZG006关键性临床试验达预设主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2684964499","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684964499?lang=zh_cn&edition=full","pubTime":"2026-11-18 17:51","pubTimestamp":1794995500,"startTime":"0","endTime":"0","summary":"泽璟制药(688266.SH)公告称,公司自主研发的1类新药注射用ZG006单药治疗晚期小细胞肺癌的关键性临床试验期中分析达到预设主要终点。独立数据监查委员会审核后判定试验达标,公司将向国家药监局药审中心提交Pre-BLA沟通交流申请,加快推进上市进程。该事项对近期业绩无重大影响。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111800034182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684095085","title":"DeepMind拆分的AI制药企业Isomorphic Labs融资50亿美元 红杉领投","url":"https://stock-news.laohu8.com/highlight/detail?id=2684095085","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684095085?lang=zh_cn&edition=full","pubTime":"2026-11-18 14:50","pubTimestamp":1794984618,"startTime":"0","endTime":"0","summary":"AI制药企业Isomorphic Labs日前宣布获得50亿美元C轮融资,Greenoaks、红杉资本、Andreessen Horowitz共同领投,其他投资者包括Thrive Capital、MGX、Temasek、英国主权人工智能基金(UK Sovereign AI Fund)及谷歌旗下GV、CapitalG。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20261118/6393061021572605168759641.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20261118/6393061021572605168759641.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n35777/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["AGIX","QTOC","BK1191","AIPO","01477","ARTY","VTHR","BK1574","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684952564","title":"大行评级丨招银国际:上调中生制药目标价至9港元,创新药商业化与国际化继续取得突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2684952564","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684952564?lang=zh_cn&edition=full","pubTime":"2026-11-18 13:58","pubTimestamp":1794981485,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["06978","BK1574","BK1161","BK1191","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684893930","title":"泽璟制药(688266)11月17日主力资金净卖出10.17万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2684893930","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684893930?lang=zh_cn&edition=full","pubTime":"2026-11-18 08:33","pubTimestamp":1794961997,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年11月17日收盘,泽璟制药报收于79.52元,下跌4.4%,换手率1.77%,成交量4.7万手,成交额3.78亿元。近5日资金流向一览见下表:泽璟制药融资融券信息显示,融资方面,当日融资买入1385.52万元,融资偿还1580.27万元,融资净偿还194.75万元。泽璟制药主营业务:化学新药及生物新药的研发、生产及销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111800009916.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK0239","688266","01477","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684935874","title":"股市必读:汇宇制药新发布《2026年第二次临时股东会会议资料》","url":"https://stock-news.laohu8.com/highlight/detail?id=2684935874","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684935874?lang=zh_cn&edition=full","pubTime":"2026-11-18 03:54","pubTimestamp":1794945251,"startTime":"0","endTime":"0","summary":"公司公告汇总:汇宇制药拟与同源康签署《和解协议书》,后者将支付3亿元和解金,分两期支付,协议生效需经双方董事会及股东会审议通过,并尚需提交公司股东大会审议。公司公告汇总2026年第二次临时股东会会议资料四川汇宇制药股份有限公司拟与浙江同源康医药股份有限公司签署《和解协议书》,就双方合作纠纷及未决诉讼案件达成一揽子、终局性和解。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111800003271.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1191","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684603692","title":"歌礼制药-B(01672)向美国FDA递交ASC36_37o FDC治疗肥胖症的新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2684603692","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684603692?lang=zh_cn&edition=full","pubTime":"2026-11-17 17:04","pubTimestamp":1794906283,"startTime":"0","endTime":"0","summary":"智通财经APP讯,歌礼制药-B 发布公告,歌礼已向美国食品药品监督管理局递交ASC36_37o FDC的新药临床试验申请,用于治疗肥胖症。“ASC36_37o FDC是首个将胰淀素受体、GLP-1R、GIPR和GCGR这四个已验证的靶点结合于单片中的每周一次口服固定剂量复方制剂。”ASC36_37o FDC的IND递交建立在歌礼每周一次口服多肽管线近期里程碑的基础之上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1524383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK4585","BK1574","LABU","MDTX","BMED","BK1515","01672","BK4588","PSYK","BK1161","IBBJ","IBBQ","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684867918","title":"港股异动 | 歌礼制药-B(01672)涨超5% ASC30_48 FDC等临床前研究亮相ObesityWeek","url":"https://stock-news.laohu8.com/highlight/detail?id=2684867918","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684867918?lang=zh_cn&edition=full","pubTime":"2026-11-17 14:07","pubTimestamp":1794895666,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,歌礼制药-B涨超5%,截至发稿,涨5.26%,报4.5港元,成交额419.38万港元。消息面上,歌礼制药-B发布公告,歌礼近日在2026年11月14日至17日于华盛顿特区召开的ObesityWeek 2026上,展示了口服小分子GIPR激动剂ASC48、GLP-1R/GIPR双靶点口服小分子ASC30_48 FDC,以及长效注射GLP-1R/GIPR/GCGR三靶点激动剂多肽ASC37的关键临床前研究结果。ASC30_48 FDC是歌礼自主研发的口服小分子复方制剂,靶向GLP-1R和GIPR,有望成为同类首创每日一次、每次一片治疗肥胖及其他代谢性疾病的口服疗法。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1524234.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1574","KCAI","BK1161","01672","BK1191","BK1515","01477","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684641014","title":"股市必读:汇宇制药新发布《2026年第二次临时股东会会议资料》","url":"https://stock-news.laohu8.com/highlight/detail?id=2684641014","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684641014?lang=zh_cn&edition=full","pubTime":"2026-11-17 02:12","pubTimestamp":1794852738,"startTime":"0","endTime":"0","summary":"截至2026年11月16日收盘,汇宇制药报收于10.26元,下跌4.29%,换手率1.94%,成交量9.86万手,成交额1.02亿元。公司公告汇总2026年第二次临时股东会会议资料四川汇宇制药股份有限公司拟与浙江同源康医药股份有限公司签署《和解协议书》,就双方合作纠纷及未决诉讼案件达成一揽子、终局性和解。同源康将向汇宇制药支付和解金共计人民币3亿元,分两期支付。协议生效需经双方董事会及股东会审议通过。该事项尚需提交公司股东大会审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111700001300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683694782","title":"歌礼制药-B(01672.HK):歌礼口服与长效注射减重临床前研究亮相ObesityWeek® 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2683694782","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683694782?lang=zh_cn&edition=full","pubTime":"2026-11-16 17:04","pubTimestamp":1794819864,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1191","01672","BK1161","01477","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683669982","title":"东吴证券:AI制药从概念验证到商业化落地 中长期关注AI平台型公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2683669982","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683669982?lang=zh_cn&edition=full","pubTime":"2026-11-16 09:40","pubTimestamp":1794793205,"startTime":"0","endTime":"0","summary":"AI生成的海量候选分子都必须经过蛋白表达、临床前湿实验验证等环节。中长期关注:1)AI平台型公司。2)AI药物获批上市有望带来行业价值重估。目前全球仍无一款完全由AI主导发现或设计的药物获得监管完全批准,一旦落地,整个赛道的估值中枢有望上移。AI有望助推新药研发整体成功率显著提升。物理机制+AI大模型融合,缓解了这两个问题。3)产业验证闭环能力:AI制药早期最大的质疑是干实验与湿实验的脱节。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1523436.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0009","BK0276","AGIX","VTHR","601555","ARTY","01477","BK1191","BK1574","CHAT","BK0188","QTOC","BK0012","BK0028","AIPO","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683765244","title":"股市必读:汇宇制药新发布《关于召开2026年第三季度业绩说明会的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2683765244","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683765244?lang=zh_cn&edition=full","pubTime":"2026-11-16 01:36","pubTimestamp":1794764170,"startTime":"0","endTime":"0","summary":"截至2026年11月13日收盘,汇宇制药报收于10.72元,下跌4.29%,换手率1.91%,成交量9.69万手,成交额1.06亿元。公司公告汇总:汇宇制药将于11月23日9:00-10:00通过上证路演中心召开2026年第三季度业绩说明会,投资者可于11月20日16:00前邮件提交问题。公司公告汇总关于召开2026年第三季度业绩说明会的公告四川汇宇制药股份有限公司将于2026年11月23日上午9:00-10:00通过上证路演中心召开2026年第三季度业绩说明会,以线上文字互动形式与投资者交流经营成果、财务状况等信息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111600000549.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683062475","title":"汇宇制药(688553)披露2026年第三季度业绩说明会安排,11月13日股价下跌4.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2683062475","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683062475?lang=zh_cn&edition=full","pubTime":"2026-11-13 22:09","pubTimestamp":1794578960,"startTime":"0","endTime":"0","summary":"截至2026年11月13日收盘,汇宇制药报收于10.72元,较前一交易日下跌4.29%,最新总市值为67.1亿元。该股当日开盘11.2元,最高11.22元,最低10.68元,成交额达1.06亿元,换手率为1.91%。近日,四川汇宇制药股份有限公司发布《关于召开2026年第三季度业绩说明会的公告》。公告显示,公司将于2026年11月23日上午9:00-10:00通过上证路演中心召开2026年第三季度业绩说明会,以线上文字互动形式与投资者交流经营成果、财务状况等信息。说明会结束后可通过该平台查看会议内容。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111300043159.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1191","01477","688553","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocumension.com","stockEarnings":[{"period":"1week","weight":-0.0844},{"period":"1month","weight":0},{"period":"3month","weight":-0.1381},{"period":"6month","weight":-0.27},{"period":"1year","weight":-0.4313},{"period":"ytd","weight":-0.3845}],"compareEarnings":[{"period":"1week","weight":-0.0519},{"period":"1month","weight":-0.0525},{"period":"3month","weight":-0.1384},{"period":"6month","weight":-0.1248},{"period":"1year","weight":-0.1326},{"period":"ytd","weight":-0.1256}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"欧康维视生物是一家主要从事眼科药物的研发和商业化的公司。该公司产品主要包括OT-401“优施莹”氟轻松玻璃体内植入剂、OT-702“博优景”阿柏西普眼内注射溶液、OT-402“维速达尔”注射用维替泊芬、OT-204“欧沁”玻璃酸钠滴眼液及OT-305“贝特舒”盐酸倍他洛尔滴眼液等。该公司产品主要用于治疗葡萄膜炎、眼底疾病、屈光矫正、干眼症(DED)、青光眼及角结膜炎等各种眼前及眼后段疾病。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.097698},{"month":2,"riseRate":0.5,"avgChangeRate":-0.037557},{"month":3,"riseRate":0.5,"avgChangeRate":0.044668},{"month":4,"riseRate":0.5,"avgChangeRate":0.015642},{"month":5,"riseRate":0.5,"avgChangeRate":0.087204},{"month":6,"riseRate":0.666667,"avgChangeRate":0.062947},{"month":7,"riseRate":0.5,"avgChangeRate":-0.003589},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.052517},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.073222},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.112188},{"month":11,"riseRate":0.285714,"avgChangeRate":-0.003149},{"month":12,"riseRate":0.5,"avgChangeRate":0.058088}],"exchange":"SEHK","name":"欧康维视生物-B","nameEN":"OCUMENSION-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧康维视生物-B,01477,欧康维视生物-B股票,欧康维视生物-B股票老虎,欧康维视生物-B股票老虎国际,欧康维视生物-B行情,欧康维视生物-B股票行情,欧康维视生物-B股价,欧康维视生物-B股市,欧康维视生物-B股票价格,欧康维视生物-B股票交易,欧康维视生物-B股票购买,欧康维视生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}